Literature DB >> 11289738

Management of undifferentiated thyroid cancer.

K B Ain1.   

Abstract

Management of thyroid carcinoma relies upon the tumour cells maintaining the differentiated functions that are typical of normal thyroid follicular cells, such as: dependence upon thyrotropin for growth, production of thyroglobulin and effective transport of iodine. Likewise, differentiated thyroid carcinomas often exhibit an auspicious clinical behaviour with a slow rate of growth and low potential for invasion and distant metastasis. These features permit therapy of disseminated tumour, effective follow-up surveillance and the assumption of a good prognosis. As each of these features are lost, the opportunities for both disease status assessment and therapeutic intervention diminish accordingly. A major obstacle is our failure to define effective systemic treatments to replace radioiodine therapy, whose loss is consonant with the loss of iodine transport and retention. The extreme of undifferentiated clinical behaviour is epitomized by anaplastic thyroid carcinoma, a rare, terminally dedifferentiated malignancy that is rapidly and invariably fatal. It is important to be attuned to clinical clues suggesting the presence of dedifferentiated tumour and related prognostic signs. This allows the application of currently limited therapeutic options and defines the need for research to develop new systemic treatments. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11289738     DOI: 10.1053/beem.2000.0106

Source DB:  PubMed          Journal:  Baillieres Best Pract Res Clin Endocrinol Metab


  7 in total

1.  Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways.

Authors:  Dingxie Liu; Mingzhao Xing
Journal:  Thyroid       Date:  2008-08       Impact factor: 6.568

2.  Fungating thyroid cancer: a complex clinical scenario.

Authors:  A S Nabawi; H F Al Wagih; M A Hemeida; T Y Koraitim; M Moussa; Tarek Ezzat
Journal:  World J Surg       Date:  2012-03       Impact factor: 3.352

Review 3.  Recent advances in molecular biology of thyroid cancer and their clinical implications.

Authors:  Mingzhao Xing
Journal:  Otolaryngol Clin North Am       Date:  2008-12       Impact factor: 3.346

4.  Evidence for transcriptional and posttranscriptional alterations of the sodium/iodide symporter expression in hypofunctioning benign and malignant thyroid tumors.

Authors:  Séverine Trouttet-Masson; Samia Selmi-Ruby; Françoise Bernier-Valentin; Valérie Porra; Nicole Berger-Dutrieux; Myriam Decaussin; Jean-Louis Peix; Agnès Perrin; Claire Bournaud; Jacques Orgiazzi; Françoise Borson-Chazot; Brigitte Franc; Bernard Rousset
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

5.  Treatment outcome of patients with anaplastic thyroid cancer: a single center experience.

Authors:  Sun Min Lim; Sang-Joon Shin; Woong Youn Chung; Cheong Soo Park; Kee-Hyun Nam; Sang-Wook Kang; Ki Chang Keum; Joo Hang Kim; Jae Yong Cho; Yun Kyoung Hong; Byoung Chul Cho
Journal:  Yonsei Med J       Date:  2012-03       Impact factor: 2.759

6.  PPARγ Promotes Growth and Invasion of Thyroid Cancer Cells.

Authors:  William M Wood; Vibha Sharma; Kevin T Bauerle; Laura A Pike; Qiong Zhou; Deborah L Fretwell; Rebecca E Schweppe; Bryan R Haugen
Journal:  PPAR Res       Date:  2011-12-12       Impact factor: 4.964

7.  Combined Effects of Baicalein and Docetaxel on Apoptosis in 8505c Anaplastic Thyroid Cancer Cells via Downregulation of the ERK and Akt/mTOR Pathways.

Authors:  Chan Ho Park; Se Eun Han; Il Seong Nam-Goong; Young Il Kim; Eun Sook Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2018-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.